The effect of ganciclovir on herpes simplex virus-mediated oncolysis

Journal of Surgical Research

Volumn 69, Issue 2, 1997, Pages 413-417

  Carroll, Nancy M ^a   Chase, Maureen ^b   Antonio Chiocca, E ^b   Tanabe, Kenneth K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL SURVIVAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; CYTOLYSIS; CYTOTOXICITY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; GLIOSARCOMA; HERPES SIMPLEX; HUMAN; HUMAN CELL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL LINE; VIRUS ADSORPTION; VIRUS GENE;

EID: 0031148328     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5089     Document Type: Conference Paper

References (29)

1. 1. Deonarain, M. P., Spooner, R. A., and Epenetos, A. A. Genetic delivery of enzymes for cancer therapy. Gene Ther. 2: 235, 1995.
2. 2. Lever, A. M. L., and Goodfellow, P. Gene therapy. Br. Med. Bull. 51: 1995.
3. 3. Wolff, J. A. (Ed.). Gene Therapeutics: Methods and Applications of Direct Gene Transfer. Boston: Birkhauser, 1994. Pp. 245-262.
4. 4. Carroll, N. M., Chiocca, E. A., and Tanabe, K. K. Gene transfer and cytotoxicity mediated by recombinant herpes simplex virus vectors. Gastroenterology (Suppl.) 110: A1377, 1996.
5. 5. Goldstein, D. J., and Weller, S. K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62: 196, 1988.
6. 6. Goldstein, D. J., and Weller, S. K. Factor(s) present in herpes simplex virus type 1 infected cells can compensate for the loss of the large unit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166: 41, 1988.
7. 7. Boviatsis, E. J., Scharf, J. M., Chase, M., Harrington, K., Kowall, N. W., Breakefield, X. O., and Chiocca, E. A. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1: 323, 1994.
8. 8. Boviatsis, E. J., Park, J. S., Sena-Esteves, M., Kramm, C. M., Chase, M., Efird, J. T., Wei, M. X., Breakefield, X. O., and Chiocca, E. A. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus that retains an intact thymidine kinase gene. Cancer Res. 54: 5745, 1994.
9. 9. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53: 5274, 1993.
10. 10. Bi, W. L., Parysek, L. M., Warnick, R., and Stambrook, P. J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4: 725, 1993.
11. 11. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 93: 1831, 1996.
12. 12. Fick, J., Barker, F. G., II, Dazin, P., Westphale, E. M., Beyer, E. C., and Israel, M. A. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA 92: 11071, 1995.
13. 13. Elshami, A. A., Saavedra, A., Zhang, H., Kucharczuk, J. C., Spray, D. C., Fishman, G. I., Amin, K. M., Kaiser, L. R., and Albelda, S. M. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3: 85, 1996.
14. 14. Colombo, B. M., Benedetti, S., Ottolenghi, S., Mora, M., Pollo, B., Poli, G., and Finocchiaro, G. The "bystander effect": Association of U87 cell death with ganciclovir-mediated apoptosis of nearby cells and the lack of effect in athymic mice. Hum. Gene Ther. 6: 763, 1995.
15. 15. Ramesh, R., Marrogi, A. J., Munshi, A., Abboud, C. N., and Freeman, S. M. In vivo analysis of the "bystander effect": A cytokine cascade. Exp. Hematol. 24: 829, 1996.
16. 16. Freeman, S. M., Ramesh, R., Shastri, M., Munshi, A., Jensen, A. K., and Marrogi, A. J. The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Cancer Lett. 92: 167, 1995.
17. 17. Carroll, N. M., Chiocca, E. A., Takahashi, K., and Tanabe, K. K. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann. Surg. 224: 323, 1996.
18. 18. Takamiya, Y., Short, M. P., Ezzeddine, Z. D., Moolten, F. L., Breakefield, X. O., and Martuza, R. L. Gene therapy of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J. Neurosci. Res. 33: 493, 1992.
19. 19. Morikawa, K., Walker, S. M., Jessup, J. M., and Fidler, I. J. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res. 48: 1943, 1988.
20. 20. Weizsaecker, M., Deen, D. F., Rosenblum, M. L., Hoshino, T., Gutin, P. H., and Barker, M. The 9L rat brain tumor: Description and application of an animal model. J. Neurol. 224: 183, 1981.
21. 21. Boviatsis, E. J., Chase, M., Wei, M. X., Takashi, T., Hurford, R. K., Jr., Kowall, N. W., Tepper, R. I., Breakefield, X. O., and Chiocca, E. A. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum. Gene Ther. 5: 183, 1994.
22. 22. Shinoura, N., Chen, L., Wani, M. A., Kim, Y. G., Larson, J. J., Warnick, R. E., Simon, M., Menon, A. G., Bi, W. L., and Stambrook, P. J. Protein and messenger RNA expression of connexin 43 in astrocytomas: Implications in brain tumor gene therapy. J. Neurosurg. 84: 839, 1996.
23. 23. Yamasaki, H., Mesnil, M., Omori, Y., Mironov, N., and Krutovskikh, V. Intercellular communication and carcinogenesis. Mutat. Res. 333: 181, 1995.
24. 24. Austin, E. A., and Huber, B. E. A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. 43: 380, 1993.
25. 25. Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., and Good, S. S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91: 8302, 1994.
26. 26. Trinh, Q. T., Austin, E. A., Murray, D. M., Knick, V. C., and Huber, B. E. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 55: 4808, 1995.
27. 27. Wood, A. J. J. Ganciclovir. N. Engl. J. Med. 335: 721, 1996.
28. 28. Marias, R., Spooner, R. A., Light, Y., Martin, J., and Springer, C. J. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56: 4735, 1996.
29. 29. Ram, Z., Walbridge, S., Shawker, T., Culver, K., Blaese, M., and Oldfield, E. H. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81: 256, 1994.